Cargando…
Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes
OBJECTIVE: This study aimed to compare cytokine and adipokine levels in patients with obesity with and without type 2 diabetes (T2D) at baseline and 6 months after Roux‐en‐Y gastric bypass (RYGB) with healthy controls. METHODS: A total of 34 patients (21 with T2D) with BMI of 30 to 45 kg/m(2) were c...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986425/ https://www.ncbi.nlm.nih.gov/pubmed/33624436 http://dx.doi.org/10.1002/oby.23093 |
_version_ | 1783668442494140416 |
---|---|
author | Katsogiannos, Petros Kamble, Prasad G. Pereira, Maria J. Sundbom, Magnus Carlsson, Per‐Ola Eriksson, Jan W. Espes, Daniel |
author_facet | Katsogiannos, Petros Kamble, Prasad G. Pereira, Maria J. Sundbom, Magnus Carlsson, Per‐Ola Eriksson, Jan W. Espes, Daniel |
author_sort | Katsogiannos, Petros |
collection | PubMed |
description | OBJECTIVE: This study aimed to compare cytokine and adipokine levels in patients with obesity with and without type 2 diabetes (T2D) at baseline and 6 months after Roux‐en‐Y gastric bypass (RYGB) with healthy controls. METHODS: A total of 34 patients (21 with T2D) with BMI of 30 to 45 kg/m(2) were compared with 25 healthy controls without obesity. Cytokines, adipokines, and peptides of relevance for inflammation and metabolism were analyzed in plasma. RESULTS: Significant decreases in weight and glycated hemoglobin A(1c) were observed. At baseline, interleukin‐6 (IL‐6), IFN‐β, IL‐18, leptin, and hepatocyte growth factor were higher in all patients with obesity compared with healthy controls. In patients without T2D, TNF‐α, IL‐1α, IL‐2, IL‐15, and visfatin were also increased, whereas bone morphogenic protein‐4 was decreased. Following RYGB, IL‐6 and hepatocyte growth factor were still increased in both groups compared with controls. In T2D patients, IFN‐β, IL‐27, IL‐1α, IL‐2, regenerating islet‐derived protein 3A, visfatin, and osteopontin were found to be increased. In patients without T2D, TNF‐α, IL‐1α, IL‐2, IL‐15, leptin, and visfatin remained increased. CONCLUSIONS: The altered cytokine profile of patients with obesity persisted after RYGB despite large weight loss and improved metabolic status, thus reflecting an inherent inflammatory state. |
format | Online Article Text |
id | pubmed-7986425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79864252021-03-25 Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes Katsogiannos, Petros Kamble, Prasad G. Pereira, Maria J. Sundbom, Magnus Carlsson, Per‐Ola Eriksson, Jan W. Espes, Daniel Obesity (Silver Spring) Original Articles OBJECTIVE: This study aimed to compare cytokine and adipokine levels in patients with obesity with and without type 2 diabetes (T2D) at baseline and 6 months after Roux‐en‐Y gastric bypass (RYGB) with healthy controls. METHODS: A total of 34 patients (21 with T2D) with BMI of 30 to 45 kg/m(2) were compared with 25 healthy controls without obesity. Cytokines, adipokines, and peptides of relevance for inflammation and metabolism were analyzed in plasma. RESULTS: Significant decreases in weight and glycated hemoglobin A(1c) were observed. At baseline, interleukin‐6 (IL‐6), IFN‐β, IL‐18, leptin, and hepatocyte growth factor were higher in all patients with obesity compared with healthy controls. In patients without T2D, TNF‐α, IL‐1α, IL‐2, IL‐15, and visfatin were also increased, whereas bone morphogenic protein‐4 was decreased. Following RYGB, IL‐6 and hepatocyte growth factor were still increased in both groups compared with controls. In T2D patients, IFN‐β, IL‐27, IL‐1α, IL‐2, regenerating islet‐derived protein 3A, visfatin, and osteopontin were found to be increased. In patients without T2D, TNF‐α, IL‐1α, IL‐2, IL‐15, leptin, and visfatin remained increased. CONCLUSIONS: The altered cytokine profile of patients with obesity persisted after RYGB despite large weight loss and improved metabolic status, thus reflecting an inherent inflammatory state. John Wiley and Sons Inc. 2021-02-23 2021-03 /pmc/articles/PMC7986425/ /pubmed/33624436 http://dx.doi.org/10.1002/oby.23093 Text en © 2021 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society (TOS) This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Katsogiannos, Petros Kamble, Prasad G. Pereira, Maria J. Sundbom, Magnus Carlsson, Per‐Ola Eriksson, Jan W. Espes, Daniel Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes |
title | Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes |
title_full | Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes |
title_fullStr | Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes |
title_full_unstemmed | Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes |
title_short | Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes |
title_sort | changes in circulating cytokines and adipokines after rygb in patients with and without type 2 diabetes |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986425/ https://www.ncbi.nlm.nih.gov/pubmed/33624436 http://dx.doi.org/10.1002/oby.23093 |
work_keys_str_mv | AT katsogiannospetros changesincirculatingcytokinesandadipokinesafterrygbinpatientswithandwithouttype2diabetes AT kambleprasadg changesincirculatingcytokinesandadipokinesafterrygbinpatientswithandwithouttype2diabetes AT pereiramariaj changesincirculatingcytokinesandadipokinesafterrygbinpatientswithandwithouttype2diabetes AT sundbommagnus changesincirculatingcytokinesandadipokinesafterrygbinpatientswithandwithouttype2diabetes AT carlssonperola changesincirculatingcytokinesandadipokinesafterrygbinpatientswithandwithouttype2diabetes AT erikssonjanw changesincirculatingcytokinesandadipokinesafterrygbinpatientswithandwithouttype2diabetes AT espesdaniel changesincirculatingcytokinesandadipokinesafterrygbinpatientswithandwithouttype2diabetes |